Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market
Forward Pharma A/S (NASDAQ:FWP) announced it received a notice from Nasdaq on December 16, 2022, stating that the company is considered a 'public shell' under Listing Rule 5101.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Forward Pharma A/S (NASDAQ:FWP) announced it received a notice from Nasdaq on December 16, 2022, stating that the company is considered a 'public shell' under Listing Rule 5101. Consequently, Nasdaq will suspend trading of Forward's American Depositary Shares on December 28, 2022, and will file a Form 25-NSE to remove its securities from listing. Forward does not plan to appeal Nasdaq's decision and intends to request suspension of its reporting obligations by filing a Form 15 with the SEC.
Positive
- None.
Negative
- Company classified as a 'public shell' by Nasdaq, threatening its trading status.
- Trading of American Depositary Shares to be suspended on December 28, 2022, indicating potential loss of investor confidence.
- Filing Form 25-NSE with the SEC suggests a complete removal from the Nasdaq Stock Market.
- Company will suspend its reporting obligations, limiting financial transparency.
Details
News Market Reaction – FWP
The recorded move for FWP in the trading session of this news was -31.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
COPENHAGEN, Denmark, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”), today announced that that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that Nasdaq believes that Forward is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. We will not appeal this determination. Therefore, we expect the trading of our American Depositary Shares on The Nasdaq Capital Market to be suspended at the opening of business on December 28, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the “SEC”), which will remove Forward’s securities from listing and registration on The Nasdaq Stock Market. Additionally, we intend to file with the SEC a Form 15 requesting the suspension of Forward’s reporting obligations.
Forward Pharma A/S Investor Relations Contact:
Forward Pharma A/S
Claus Bo Svendsen, MD, PhD
Chief Executive Officer
Investor Relations
investors@forward-pharma.com
Forward Pharma A/S
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.